A052020 Share Price Performance
Recent A052020 News & Updates
No updates
STCube, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -308.91
- Gross Margin
- 7.93%
- Net Profit Margin
- -199.86%
- Debt/Equity Ratio
- 0%
STCube, Inc. Competitors
About A052020
- Founded
- 1989
- Employees
- 13
- CEO
- WebsiteView website
STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pipeline consists of various anti-cancer drugs, including anti PD-L1 Ab and anti PD-1 Ab in preclinical study, and anti STT-005 for solid tumor; anti STT-003 Ab in phase-1 for lung, head, and neck cancer; small molecule STT-011 inhibitor candidate development for pancreatic cancer; anti STT-012 Ab for breast and prostate cancer; and anti STT-013 Ab for solid tumor. The company was formerly known as Schem Co., Ltd. and changed its name to STCube, Inc. in April 2008. The company was founded in 1989 and is headquartered in Seoul, South Korea.
South Korean Market Performance
- 7 Days: 1.5%
- 3 Months: 24.6%
- 1 Year: 13.5%
- Year to Date: 32.5%
The market has climbed 1.5% in the last 7 days, lead by the Information Technology sector with a gain of 5.3%. In the last year, the market has climbed 14%. Looking forward, earnings are forecast to grow by 21% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading